OPKO Health (NASDAQ:OPK) Stock Price Up 3.3%

OPKO Health, Inc. (NASDAQ:OPK - Get Free Report)'s share price shot up 3.3% during mid-day trading on Wednesday . The company traded as high as $1.25 and last traded at $1.25. 469,300 shares changed hands during trading, a decline of 97% from the average session volume of 13,934,207 shares. The stock had previously closed at $1.21.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Barrington Research restated an "outperform" rating and set a $1.50 price target on shares of OPKO Health in a research report on Monday, April 1st. Piper Sandler reaffirmed an "overweight" rating and issued a $5.00 target price on shares of OPKO Health in a research report on Monday, April 1st. HC Wainwright reissued a "buy" rating and set a $3.00 price target on shares of OPKO Health in a research report on Wednesday, April 3rd. Finally, StockNews.com cut OPKO Health from a "hold" rating to a "sell" rating in a research note on Friday, March 1st.

OPKO Health Trading Up 3.3 %

The stock has a fifty day moving average of $1.07 and a 200 day moving average of $1.24. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.22 and a current ratio of 1.55. The company has a market capitalization of $871.24 million, a P/E ratio of -5.00 and a beta of 1.82.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). The business had revenue of $181.90 million for the quarter, compared to the consensus estimate of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The company's revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. As a group, equities research analysts anticipate that OPKO Health, Inc. will post -0.33 EPS for the current fiscal year.

Insider Transactions at OPKO Health

In related news, Director Richard M. Krasno acquired 30,000 shares of the company's stock in a transaction on Monday, January 29th. The stock was acquired at an average price of $0.99 per share, with a total value of $29,700.00. Following the acquisition, the director now directly owns 103,333 shares of the company's stock, valued at $102,299.67. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In other OPKO Health news, Director Richard M. Krasno bought 30,000 shares of the business's stock in a transaction that occurred on Monday, January 29th. The stock was purchased at an average cost of $0.99 per share, with a total value of $29,700.00. Following the completion of the acquisition, the director now owns 103,333 shares in the company, valued at approximately $102,299.67. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Phillip Md Et Al Frost purchased 400,000 shares of OPKO Health stock in a transaction that occurred on Thursday, January 18th. The stock was acquired at an average price of $0.97 per share, for a total transaction of $388,000.00. Following the transaction, the chief executive officer now directly owns 205,368,225 shares of the company's stock, valued at approximately $199,207,178.25. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 5,030,000 shares of company stock valued at $4,810,700. 47.26% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. IPG Investment Advisors LLC purchased a new stake in shares of OPKO Health in the fourth quarter worth approximately $30,000. Verition Fund Management LLC bought a new position in OPKO Health in the second quarter worth approximately $36,000. River Wealth Advisors LLC purchased a new position in OPKO Health during the 3rd quarter worth $38,000. Guggenheim Capital LLC bought a new stake in OPKO Health during the 1st quarter valued at $38,000. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of OPKO Health in the 1st quarter worth $39,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.